Announced Wed, 8 Jul · 12:57 IST
Suven Life Sciences allots 1.85 crore shares via warrant conversion, raises Rs 249 crore
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+10.2%1-day move
₹317.50
prior close
₹322.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.8+0.8+2.0+10.2+12.3+13.1+9.9+12.5+2.2————
Up moveDown movePending
AI summary
Suven Life Sciences allotted 1,85,70,133 equity shares at Rs 134 each to 17 non-promoter entities upon conversion of warrants, raising Rs 248.84 crore. Paid-up capital rises to 28,25,62,686 shares. Board also re-appointed Dr. Vajja Sambasiva Rao as Independent Director for 5 years from Jan 2027 and approved Singapore wholly owned subsidiary Suven Neurosciences Pte. Ltd. for neurological therapeutics with USD 100 million investment.
Likely market impact
Slight dilution for shareholders but company gets Rs 249 crore cash. Singapore unit signals global expansion into neurological drugs.